If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about…
Read More
Enveric Biosciences Inc (NASDAQ: ENVB) will soon have a patent in hand for its EVM301 non-psychoactive, psychedelic-inspired drugs. The United States Patent and Trademark Office just gave Enveric a notice…
Read More
For years, the psychedelic renaissance focused on one clear idea. If you could deliver a guided psychedelic experience safely and predictably, you could lift people out of stubborn depression, trauma,…
Read More
The current state of the mental health system is a conversation that echoes in the halls of policy-making, the corners of social advocacy, and within the private struggles of individuals…
Read More
Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and…
Read More
Enveric Biosciences recently announced that it has hired intellectual property powerhouse Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by rival Gilgamesh Pharmaceuticals against Enveric's issued…
Read More
Microcap Enveric Biosciences (NASDAQ:ENVB) is threatening to take legal action against AbbVie (NYSE:ABBV) as it believes that the latter's major depressive disorder candidate bretisilocin, which it said it would acquire…
Read More
In the rush to stake a claim in next-generation mental health treatments, biotech headlines are dominated by billion-dollar acquisitions and bold clinical projections. But in the fine print—in courtrooms, patent…
Read More
Enveric Biosciences (NASDAQ: ENVB) has hired prominent intellectual property law firm Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals, which earlier this year agreed…
Read More
When AbbVie wrote a $1.2 billion cheque for Gilgamesh Pharmaceuticals’ Bretisilocin, it wasn’t just buying a drug, it was buying a future. That future, once dismissed as fringe science, is now being…
Read More
